The nonhuman primate as a model for type 2 diabetes

Lynley D. Pound, Paul Kievit, Kevin Grove

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

PURPOSE OF THE REVIEW: Although rodent models provide insight into the mechanisms underlying type 2 diabetes mellitus (T2DM), they are limited in their translatability to humans. The nonhuman primate (NHP) shares important metabolic similarities with the human, making it an ideal model for the investigation of type 2 diabetes and use in preclinical trials. This review highlights the key contributions in the field over the last year using the NHP model. RECENT FINDINGS: The NHP has not only provided novel insight into the normal and pathological processes that occur within the islet, but has also allowed for the preclinical testing of novel pharmaceutical targets for obesity and T2DM. Particularly, administration of fibroblast growth factor-21 in the NHP resulted in weight loss and improvements in metabolic health, supporting rodent studies and recent clinical trials. In addition, the NHP was used to demonstrate that a novel melanocortin-4 receptor agonist did not cause adverse cardiovascular effects. Finally, this model has been used to provide evidence that glucagon-like peptide-1-based therapies do not induce pancreatitis in the healthy NHP. SUMMARY: The insight gained from studies using the NHP model has allowed for a better understanding of the processes driving T2DM and has promoted the development of well tolerated and effective treatments.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume21
Issue number2
DOIs
StatePublished - Apr 2014

Fingerprint

Type 2 Diabetes Mellitus
Primates
Rodentia
Receptor, Melanocortin, Type 4
Glucagon-Like Peptide 1
Pathologic Processes
Pancreatitis
Weight Loss
Obesity
Clinical Trials
Health
Pharmaceutical Preparations

Keywords

  • fibroblast growth factor-21
  • glucagon-like peptide-1
  • melanocortin-4 receptor
  • nonhuman primate
  • type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

The nonhuman primate as a model for type 2 diabetes. / Pound, Lynley D.; Kievit, Paul; Grove, Kevin.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 21, No. 2, 04.2014, p. 89-94.

Research output: Contribution to journalArticle

@article{a61cd12512284f0d9869d1b3b4ce8eae,
title = "The nonhuman primate as a model for type 2 diabetes",
abstract = "PURPOSE OF THE REVIEW: Although rodent models provide insight into the mechanisms underlying type 2 diabetes mellitus (T2DM), they are limited in their translatability to humans. The nonhuman primate (NHP) shares important metabolic similarities with the human, making it an ideal model for the investigation of type 2 diabetes and use in preclinical trials. This review highlights the key contributions in the field over the last year using the NHP model. RECENT FINDINGS: The NHP has not only provided novel insight into the normal and pathological processes that occur within the islet, but has also allowed for the preclinical testing of novel pharmaceutical targets for obesity and T2DM. Particularly, administration of fibroblast growth factor-21 in the NHP resulted in weight loss and improvements in metabolic health, supporting rodent studies and recent clinical trials. In addition, the NHP was used to demonstrate that a novel melanocortin-4 receptor agonist did not cause adverse cardiovascular effects. Finally, this model has been used to provide evidence that glucagon-like peptide-1-based therapies do not induce pancreatitis in the healthy NHP. SUMMARY: The insight gained from studies using the NHP model has allowed for a better understanding of the processes driving T2DM and has promoted the development of well tolerated and effective treatments.",
keywords = "fibroblast growth factor-21, glucagon-like peptide-1, melanocortin-4 receptor, nonhuman primate, type 2 diabetes",
author = "Pound, {Lynley D.} and Paul Kievit and Kevin Grove",
year = "2014",
month = "4",
doi = "10.1097/MED.0000000000000043",
language = "English (US)",
volume = "21",
pages = "89--94",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The nonhuman primate as a model for type 2 diabetes

AU - Pound, Lynley D.

AU - Kievit, Paul

AU - Grove, Kevin

PY - 2014/4

Y1 - 2014/4

N2 - PURPOSE OF THE REVIEW: Although rodent models provide insight into the mechanisms underlying type 2 diabetes mellitus (T2DM), they are limited in their translatability to humans. The nonhuman primate (NHP) shares important metabolic similarities with the human, making it an ideal model for the investigation of type 2 diabetes and use in preclinical trials. This review highlights the key contributions in the field over the last year using the NHP model. RECENT FINDINGS: The NHP has not only provided novel insight into the normal and pathological processes that occur within the islet, but has also allowed for the preclinical testing of novel pharmaceutical targets for obesity and T2DM. Particularly, administration of fibroblast growth factor-21 in the NHP resulted in weight loss and improvements in metabolic health, supporting rodent studies and recent clinical trials. In addition, the NHP was used to demonstrate that a novel melanocortin-4 receptor agonist did not cause adverse cardiovascular effects. Finally, this model has been used to provide evidence that glucagon-like peptide-1-based therapies do not induce pancreatitis in the healthy NHP. SUMMARY: The insight gained from studies using the NHP model has allowed for a better understanding of the processes driving T2DM and has promoted the development of well tolerated and effective treatments.

AB - PURPOSE OF THE REVIEW: Although rodent models provide insight into the mechanisms underlying type 2 diabetes mellitus (T2DM), they are limited in their translatability to humans. The nonhuman primate (NHP) shares important metabolic similarities with the human, making it an ideal model for the investigation of type 2 diabetes and use in preclinical trials. This review highlights the key contributions in the field over the last year using the NHP model. RECENT FINDINGS: The NHP has not only provided novel insight into the normal and pathological processes that occur within the islet, but has also allowed for the preclinical testing of novel pharmaceutical targets for obesity and T2DM. Particularly, administration of fibroblast growth factor-21 in the NHP resulted in weight loss and improvements in metabolic health, supporting rodent studies and recent clinical trials. In addition, the NHP was used to demonstrate that a novel melanocortin-4 receptor agonist did not cause adverse cardiovascular effects. Finally, this model has been used to provide evidence that glucagon-like peptide-1-based therapies do not induce pancreatitis in the healthy NHP. SUMMARY: The insight gained from studies using the NHP model has allowed for a better understanding of the processes driving T2DM and has promoted the development of well tolerated and effective treatments.

KW - fibroblast growth factor-21

KW - glucagon-like peptide-1

KW - melanocortin-4 receptor

KW - nonhuman primate

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84896817792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896817792&partnerID=8YFLogxK

U2 - 10.1097/MED.0000000000000043

DO - 10.1097/MED.0000000000000043

M3 - Article

C2 - 24569549

AN - SCOPUS:84896817792

VL - 21

SP - 89

EP - 94

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 2

ER -